Skip to main content
SpringerLink
Log in

Organization of Care and Treatment

  • Chapter
  • First Online:
Current Schizophrenia

  • 2158 Accesses

Abstract

Good clinical practice requires a close, cooperative, and multidisciplinary treatment network for patients and relatives. The effects of schizophrenia on a patient’s life can create such difficulties and impairments that multidisciplinary care providers have to work together closely.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. The 2009 National Institute for Health and Clinical Excellence guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition). The National Institute for Health and Clinical Excellence website. www.nice.org.uk/guidance/CG82/NICEGuidance. Accessed April 2, 2012.

  2. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd compendium. Arlington, VA: APA, 2004.

    Google Scholar 

  3. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36:94-103.

    Google Scholar 

  4. Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry. 2005;50(13 suppl 1):7S-57S.

    Google Scholar 

  5. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry. 2005;39:1-30.

    Google Scholar 

  6. Weiden PJ, Preskorn SH, Fahnestock PA, Carpenter D, Ross R, Docherty JP. Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a roadmap. J Clin Psychiatry. 2007;68(suppl 7):1-48.

    Google Scholar 

  7. Lambert M. Taschenatlas der Pharmakotherapie psychotischer Störungen. Stuttgart, Germany: Thieme-Verlag, 2009.

    Google Scholar 

  8. Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand. 2011;123:411-422.

    Google Scholar 

  9. Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry. 1994;55(suppl B):133-136.

    Google Scholar 

  10. The International Psychopharmacology Algorithm Project schizophrenia algorithm. The International Psychopharmacology Algorithm Project website. www.ipap.org/pdf/schiz/ IPAP_Schiz_flowchart20060327.pdf. Accessed April 2, 2012.

  11. Huber CG, Naber D, Lambert M. Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors. Expert Opin Pharmacother. 2008;12:2027-2038.

    Google Scholar 

  12. Lambert M, Naber D, Huber CG. Management of incomplete remission and treatment resistance in first-episode psychosis. Expert Opin Pharmacother. 2008;9:2039-2051.

    Google Scholar 

  13. Bruch SM, Zeller S. Agitation I: overview of agitation and violence. In: Glick RL, Berlin JS, Fishkind AB, Zeller SL, eds. Emergency Psychiatry: Principles and Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:117-124.

    Google Scholar 

  14. Allen MH, Currier GW, Carpenter D, et al. Treatment of behavioral emergencies. J Psychiatr Pract. 2005;11:5-108.

    Google Scholar 

  15. Lambert M, Naber D, eds. Current Schizophrenia. 2nd edn. New York, NY: Springer Healthcare; 2009.

    Google Scholar 

  16. Stroup TS, Marder SR, Lieberman JA. Pharmacotherapies. In: Lieberman JA, Stroup TS, Perkins DO, eds. Essential Schizophrenia. Arlington, VA: American Psychiatric Publishing, Inc.; 2012:173-206.

    Google Scholar 

  17. Haldol [package insert]. Titusville, NJ: Ortho-McNeil Neurologics; 2011.

    Google Scholar 

  18. Zyprexa [package insert]. Indianapolis, IN: Eli Lilly and Company; 2011.

    Google Scholar 

  19. Geodon [package insert].New York, NY: Roerig; 2010.

    Google Scholar 

  20. Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: a 4-year review of ziprasidone.CNS Spectr. 2005;10(suppl 17):1-20.

    Google Scholar 

  21. Fitzgerald P. Long-acting antipsychotic medication, restraint and treatment in the management of acute psychosis. Aust N Z J Psychiatry. 1999;33:660-666.

    Google Scholar 

  22. Cookson J, Taylor D, Katona C. Violence: assessing risk and acute tranquilisation. In: Use of Drugs in Psychiatry. 5th edn. London, England: The Royal College of Psychiatrists; 2002:154-162.

    Google Scholar 

  23. Addington D, Bouchard R-H, Goldberg J, et al. Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry. 2005;50(suppl 1):1S-56S.

    Google Scholar 

  24. Droperidol injection [package insert]. Shirley, NY: American Regent, Inc.; 2009.

    Google Scholar 

  25. Clozaril [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.

    Google Scholar 

  26. Kerwin RW, Bolonna A. Management of clozapine-resistant schizophrenia. Adv Psychiatr Treat. 2005;11:101-106.

    Google Scholar 

  27. Remington G, Saha A, Chong S-A, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs. 2005;19:843-872.

    Google Scholar 

  28. Nasrallah HA, Tandon R. Classic antipsychotic medications. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed. Arlington, VA: American Psychiatric Publishing, Inc.; 2009:533-554.

    Google Scholar 

  29. Dev VJ, Rosenberg T, Krupp P. Agranulocytosis and clozapine. BMJ. 1994;309:54.

    Google Scholar 

  30. Davis, JM, Kane JM, Marder SR, et al. Dose response of prophylactic antipsychotics. J Clin Psych. 1993;54(suppl):24-30.

    Google Scholar 

  31. Anderson CM, Reiss DJ, Hogarty GE. Schizophrenia and the Family: A Practitioner’s Guide to Psychoeducation and Management. New York, NY: The Guilford Press; 1986.

    Google Scholar 

  32. Kane JM. Treatment programme and long-term outcome in chronic schizophrenia. Acta Psychiatr Scand. 1990;82(suppl 358):151-157.

    Google Scholar 

  33. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-247.

    Google Scholar 

  34. Wyatt RJ. Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull. 1997;23:3-9.

    Google Scholar 

  35. Bakker PR, de Groot IW, van Os J, van Harten PN. Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder. PLoS One. 2011;6:e25588.

    Google Scholar 

  36. Halliday J, Farrington S, Macdonald S, MacEwan T, Sharkey V, McCreadie R. Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. Br J Psychiatry. 2002;181:422-427.

    Google Scholar 

  37. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486-487.

    Google Scholar 

  38. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21:151-156.

    Google Scholar 

  39. Tenback DE, van Harten PN. Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol. 2011;98:211-230.

    Google Scholar 

  40. Gillman PK. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord. 2010;25:1780-1790.

    Google Scholar 

  41. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007 Jun;164:870-876.

    Google Scholar 

  42. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65:464-470.

    Google Scholar 

  43. Pelonero AL, Levenson JL, Pandurangi AK.. Neuroleptic malignant syndrome: a review. Psychiatr Serv. 1998;49:1163-1172.

    Google Scholar 

  44. De Hert M, Schreurs V, Vancampfort D, van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8:15-22.

    Google Scholar 

  45. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – the evidence report. Obes Res. 1998;6(suppl 2):51S-209S.

    Google Scholar 

  46. Zipursky RB, Gu H, Green AI, Perkins DO, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537-543.

    Google Scholar 

  47. Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW. Weight gain induced by clozapine. Eur Neuropsychopharmacol. 1995;5:437-440.

    Google Scholar 

  48. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51:480-491.

    Google Scholar 

  49. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). National Institutes of Health website. www.nhlbi.nih.gov/guidelines/cholesterol/ atp3xsum.pdf. Accesed April 2, 2012.

  50. De Hert M, van Winkel R, Van Eyck D, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health. 2006;2:14-26.

    Google Scholar 

  51. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.

    Google Scholar 

  52. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45-53.

    Google Scholar 

  53. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65:267-272.

    Google Scholar 

  54. Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol. 2008;22:46-55.

    Google Scholar 

  55. Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol. 2008;22:90-97.

    Google Scholar 

  56. Dursun SM, Wildgust HJ, Strickland P, Goodwin GM, Citrome L, Lean M. The emerging physical health challenges of antipsychotic associated hyperprolactinaemia in patients with serious mental illness. J Psychopharmacol. 2008;22:3-5.

    Google Scholar 

  57. Cutler AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology. 2003;28 (suppl 1):69-82.

    Google Scholar 

  58. Hellewell, JSE. Tolerability and patient satisfaction as determinants of treatment choice in schizophrenia: a multi-national survey of the attitudes and perceptions of psychiatrists towards novel and conventional antipsychotics. Poster presented at: 13th European College of Neuropsychopharmacology Congress; September 9-13, 2000; Munich, Germany.

    Google Scholar 

  59. Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev. 2010(12): CD000088.

    Google Scholar 

  60. Mari JJ, Streiner DL. An overview of family interventions and relapse on schizophrenia: meta-analysis of research findings. Psychol Med. 1994;24:565-578.

    Google Scholar 

  61. Turkington D, Kingdon D, Weiden PJ. Cognitive behavior therapy for schizophrenia. Am J Psychiatry. 2006;163:365-373.

    Google Scholar 

  62. World Health Organization. Mental Health and Work: Impact, Issues and Good Practices. Geneva, Switzerland: World Health Organization; 2000.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Psychotherapy, Center for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany

    Martin Lambert & Dieter Naber

Authors
  1. Martin Lambert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dieter Naber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Lambert .

Editor information

Editors and Affiliations

  1. Martinistr. 52, Hamburg, 20246, Hamburg, Germany

    Martin Lambert

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Healthcare, a part of Springer Science+Business Media

About this chapter

Cite this chapter

Lambert, M., Naber, D. (2013). Organization of Care and Treatment. In: Lambert, M. (eds) Current Schizophrenia. Springer Healthcare, Heidelberg. https://doi.org/10.1007/978-1-908517-68-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-908517-68-5_3

  • Published:

  • Publisher Name: Springer Healthcare, Heidelberg

  • Print ISBN: 978-1-908517-46-3

  • Online ISBN: 978-1-908517-68-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation